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Objectives: To determine the effects of lixisenatide, a new once-daily (QD) glucagon-like peptide-1 receptor
agonist, on postprandial glucose (PPG) and gastric emptying, and the relationship between these effects in
patients with type 2 diabetes mellitus (T2DM).
Methods: Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study
with treatment duration of 28 days in patients with T2DM receiving ≤2 oral antidiabetic drugs. Lixisenatide
was injected subcutaneously using an ascending dose range (5–20 μg) increased every ﬁfth day in incre-
ments of 2.5 μg. Blood glucose was determined before and after three standardized meals (breakfast,
lunch, and dinner). Gastric emptying of the standardized breakfast was determined by a 13C-octanoic acid
breath test at baseline (Day−1) and at Day 28.
Results: A total of 21 and 22 patients were randomized to lixisenatide 20 μg QD and placebo, respectively.
With lixisenatide 20 μg QD, there was a reduction in PPG when compared with placebo after breakfast
(p b 0.0001), lunch (p b 0.001) and dinner (p b 0.05). Hence, lixisenatide 20 μg administered in the
morning exhibited a pharmacodynamic effect on blood glucose throughout the day. Gastric emptying (50%
emptying time) increased substantially from baseline with lixisenatide 20 μg QD, but not with placebo
(change from baseline ±SD: −24.1 ± 133.1 min for placebo and 211.5 ± 278.5 min for lixisenatide;
p b 0.01). There was an inverse relationship between PPG area under the curve after breakfast and gastric
emptying with lixisenatide 20 μg QD (n = 17, r2 = 0.51, p b 0.05), but not with placebo.
Conclusions: In this study, lixisenatide at a dose of 20 μg QD reduced postprandial glycemic excursions in
patients with T2DM, possibly as a result of sustained slowing of gastric emptying.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Glucagon-like peptide-1 (GLP­1) receptor agonists are now used
widely in the management of type 2 diabetes (T2DM) [1]. These agents
have beneﬁcial effects on both fasting and postprandial glycemia, with
concomitant improvements in ‘average’ glycemic control, as assessed
by glycated hemoglobin (HbA1c) [1–4]. As a class, GLP­1 receptor ago-
nists are known to simultaneously stimulate insulin secretion in a
glucose-dependent manner and suppress glucagon release [1–3]. This
glucose dependency means that, unlike with insulin or insulin secreta-
gogues (sulfonylurea) therapy, the risk of hypoglycemia is low. More-
over, the use of GLP-1 agonists is associated with weight loss, rather
than the weight gain that is often observed with insulin therapy.GmbH, R & DDiabetes Division/
, Germany, 65926 Frankfurt am
z).
Y-NC-ND license.There are substantial differences between GLP-1 receptor agonists
(currently available or in development) in terms of their duration of ac-
tion and propensity for gastrointestinal effects following subcutaneous
administration [3]. GLP-1 receptor agonists do not improve glycemia
solely as a result of their effect on islet cell function in that they also
slow gastric emptying [4,5]. The latter is known to be an important
determinant of postprandial glycemic excursions in healthy individuals
[6] and in patients with T2DM [7,8]. Slowing gastric emptying prolongs
absorption of meal-derived glucose and has the capacity to blunt post-
prandial glucose (PPG) excursions [8,9]. The rate of gastric emptying
varies widely between healthy individuals [10], and in patients with
long-standing T2DM there is a high prevalence of delayed, and occa-
sionally more rapid, gastric emptying, so that the inter-individual vari-
ation is even greater among these patients [11]. Importantly, the effects
of exogenous GLP-1 on PPG and insulin appear to be related to themag-
nitude of slowing of gastric emptying [9,12,13]. Moreover, this slowing
is dependent on the baseline rate of gastric emptying, so that when
emptying is already slow, GLP-1 has little, if any, effect [9,12]. A recent
study suggests that there may be rapid tachyphylaxis to the slowing
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liquid testmealswere given to healthy subjects at an interval of 4 h dur-
ing a continuous, intravenous GLP-1 infusion, GLP-1 delayed emptying
of both drinks substantially, but the magnitude of this slowing was
less with the second drink [14]. There is evidence for tachyphylaxis of
the slowing of gastric emptying with marketed longer-acting GLP-1 re-
ceptor agonists, liraglutide once-daily (QD) and exenatide once-weekly
(LAR); this is not observed with the shorter-acting agent exenatide
twice-daily (BID) [5,15,16]. Hence, there appear to be substantial differ-
ences between GLP-1 receptor agonists regarding their effect on gastric
emptying, which is relevant to their impact on HbA1c and, particularly,
postprandial glycemia.
Lixisenatide is a new once-daily GLP-1 receptor agonist. In a dose-
ranging study in patients with T2DM inadequately controlled withmet-
formin, lixisenatide at a dose of 20 μg QD demonstrated the best
efﬁcacy-to-tolerability ratio [17]. Lixisenatide has demonstrated efﬁcacy
as monotherapy, in combination with oral antidiabetic drugs, and as
add-on to basal insulin, with particular efﬁcacy in reducing PPG excur-
sions [18–26]. On February 1st 2013, the European Commission granted
Marketing Authorization in Europe for lixisenatide for the treatment of
adults with T2DM [27].
The objective of the current analysis was to determine the effects
of lixisenatide 20 μg QD administered for 28 days on the blood glu-
cose response to a standardized breakfast, lunch, and dinner, and
evaluate the relationship between the effects of lixisenatide on post-
prandial blood glucose with those on gastric emptying in patients
with T2DM.
2. Materials and methods
Presented data were derived from study ACT6011, which was a
randomized, placebo-controlled, double-blind, parallel-group design
study with a 28-day treatment duration, involving three centers in
South Africa. The study was approved by the relevant institutional re-
view boards or ethics committees and was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice. All pa-
tients provided written informed consent prior to their participation.
Safety and tolerability were monitored throughout the study. Adverse
events reported spontaneously by the subject or observed by the in-
vestigator were recorded.
2.1. Study objectives
The objectives of this study were to assess the effect of lixisenatide
on postprandial blood glucose after a standardized breakfast, lunch,
and dinner, and on gastric emptying, C-peptide, serum insulin and
glucagon concentration after a standardized breakfast, fasting blood
glucose (FBG), HbA1c, as well as safety and tolerability. The relation-
ship between the change in area under the curve (AUC) for PPG and
half-life of gastric emptying were assessed in a post-hoc linear regres-
sion analysis.
2.2. Patients
Males and females, 18–70 years old, body mass index (BMI)
≤35 kg/m2, with stable T2DM treated with up to two oral antidiabetic
drugs (metformin and/or sulfonylurea) under routine care of a physician
for diabetes, with a stable diabetic prescription history (i.e. within the
previous 3 months and including adherence to ‘reasonable’ dietary
guidelines), reasonable glucose control and HbA1c ≥7.0% and ≤10.0%
were eligible for inclusion. Exclusion criteria included: evidence or histo-
ry of renal, hepatic or cardiovascular disease, pancreatitis, gastric
surgery, clinically relevant gastrointestinal disease (including known
gastroparesis), previous exposure to GLP-1 receptor agonists, insulin
use within the preceding 3 months, use of thiazolidinediones or drugspotentially affecting either insulin secretion or gastrointestinal motility
(except beta-blockers and sulfonylureas).
2.3. Protocol
Data were derived from participants (hospitalized from the eve-
ning of Day−2 to the morning of Day 29) randomized to subcutane-
ous once-daily lixisenatide or placebo administered in the morning
on Days 1 to 28. An additional lixisenatide twice-daily (morning
and evening) treatment arm was included in the original study but
these data were not included in the current analysis, given that
lixisenatide 20 μg QD has been subsequently demonstrated to pro-
vide the best efﬁcacy-to-tolerability ratio [17]. Lixisenatide was
injected at an initial dose of 5 μg QD and the dose per injection was
increased in increments of 2.5 μg every ﬁfth day, to a maximum
level of 20 μg QD, administered during the last 4 days (Days 25 to
28). Injections were administered subcutaneously in the morning
15 min before breakfast. Reduction from a given dose level was con-
sidered following two or more episodes of vomiting on >2 consecu-
tive days; and/or two or more episodes of marked nausea (of severe
intensity for >2 h) on >2 consecutive days. In each subject, decisions
relating to dose progression were made by an investigator based on
evaluation of blinded safety and tolerability data.
Each subject received three standardized test meals (breakfast,
lunch and dinner) on Day−1 (1 day prior to study treatment) and on
Day 28. The caloric content of eachmealwas ~450 kcalwith 50% energy
as carbohydrate, 23% as fat and 27% as protein. For the determination of
gastric emptying rate, 13C-octanoic acid was added to the breakfast
meal, as described below. Time zerowas considered to be the beginning
of the breakfast meal, which was consumed in 10 min. Blood glucose
was determined at pre-speciﬁed time points with 24-hour proﬁling.
2.4. Assessments
At baseline, Day−1 and on the fourth day of each dose level, venous
blood samples were collected at pre-speciﬁed times for measurement of
blood glucose before and after the standardized breakfast, lunch and din-
ner. Blood glucose was determined at the bedside with a Yellow Springs
Instruments 2300S glucose analyzer using the glucose oxidase method.
Serum samples were analyzed for insulin and C-peptide concentration
using radioimmunoassay methods (Linco Research Inc.). HbA1c was ana-
lyzed using an immunological assay (Tina-quant® Hemoglobin A1C II,
Roche Diagnostics, Germany). Change in HbA1c was recorded from base-
line to Day 29.
PPG–AUCswere calculated as the area under the time–concentration
curve from 0:14 h after the morning injection, just before breakfast,
until 4:55 h after the morning injection (PPG–AUCbreakfast), from
5:14 h after the morning injection (just before lunch) until 4:55 h
after lunch (PPG–AUClunch) and from 10:14 h after the morning injec-
tion (just before dinner) until 4:55 h after dinner (PPG–AUCdinner).
Blood samples for determination of C-peptide, insulin and glucagon
were collected on Day−1 and Day 28 after a standardized breakfast
and were analyzed as the area under the time–concentration curve
from 0:14 until 4:55 h (AUC) relative to the pre-breakfast value.
2.5. Gastric emptying
Gastric emptying at breakfast was determined by a 13C-octanoic acid
breath test [28] on Days−1 and 28. Patients received a standardized
breakfast consisting of a scrambled egg with the yolk infused with
100 mg of 13C-octanoic acid (manufacturer: Euriso-Top, France). The
yolk and egg white were cooked separately, but administered together
with two-and-a-quarter slices of white bread, 45 g low-fat cottage
cheese, one teaspoon of margarine, a quarter teaspoon mayonnaise or
olive oil, 100 g fruit yoghurt, and one apple or peach, followed immedi-
ately by 150 mL of non-sparkling water. The meal was consumed in less
Table 1
Baseline demographic and clinical characteristics.
Lixisenatide
(n = 21)
Placebo
(n = 22)
Male, n (%) 11 (52.4) 11 (50.0)
Female, n (%) 10 (47.6) 11 (50.0)
Race, n (%)
Caucasian 9 (42.9) 7 (31.8)
Other 4 (19.0) 3 (13.6)
Age, years, mean (±SD) 53.7 (±7.1) 53.8 (±6.6)
Duration of known diabetes, years, mean (±SD) 6.1 (±4.0) 5.7 (±3.8)
Body mass index, kg/m2, mean (±SD) 31.4 (±4.1) 29.8 (±3.8)
HbA1c, %, mean (±SD) 8.5 (±1.0) 8.9 (±1.1)
Fasting blood glucose, mmol/L, mean (±SD) 8.7 (±1.8) 8.8 (±1.7)
OADs, n (%)
Sulfonylureas 7 (33.3) 5 (22.7)
Metformin 4 (19) 3 (13.6)
Both 10 (47.6) 14 (63.6)
SD = standard deviation, N = number of patients; OAD = oral antidiabetic drug.
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as a result of gastric emptying, the labeled octanoic acid reaches the duo-
denum (rate-limiting step), where it is rapidly absorbed and transported
to the liver where it is oxidized, so that the 13CO2/12CO2 ratio over time
provides a measure of gastric emptying [28]. End-expiratory breath sam-
ples were obtained immediately before the breakfast meal (baseline),
then every 15 min for 2 h and then every 30 min for another 2 husing in-
frared isotope (IRIS)-breath bags (double-chamber) with a volume of
0.12 L (Wagner Analysen Technik, Bremen, Germany). The ratio of
13CO2/12CO2 in the breath was determined by IRIS analyzer (IRIS®,
Wagner Analysen Technik, Bremen, Germany). These data were used to
determine the 50% gastric emptying time (t1/2).
2.6. Safety evaluation
Safety and tolerability assessments were based on adverse events,
including symptomatic hypoglycemia (deﬁned as an event with clin-
ical symptoms that were considered to result from hypoglycemia),
safety laboratory (standard hematology, clinical chemistry and uri-
nalysis parameters), vital signs (blood pressure and pulse rate),
12-lead electrocardiogram (ECG), local tolerability at the site of injec-
tion, and anti-lixisenatide antibodies.
2.7. Statistical analyses
The primary analysis population was the modiﬁed intent-to-treat
population, which included all patients who were randomized and
received at least one dose of study medication. Patients who were
randomized but not treated with study medication were not included
in the analysis.
Demographic and background characteristics were summarized
for the analysis population of all treated patients as well as by treat-
ment group to assess the comparability of the treatment groups at
baseline and to characterize the population. Continuous variables
were summarized using the following descriptive statistics: number
of patients (N), mean and standard deviation. Absolute and relative
frequency distributions are provided for categorical data. Baseline de-
mographic variables were tested for overall between-group homoge-
neity using all patients with available data. The continuous variables
(age, BMI, time since diagnosis of diabetes and FBG) were compared
using an analysis of variance model with treatment as ﬁxed effect.
The general association Cochran–Mantel–Haenszel test was used for
categorical data such as sex and race. The statistical methods for the
analysis of baseline data were used in a purely exploratory manner.
PPG–AUC at breakfast, lunch and dinner, maximum PPG and
breakfast AUCs of C-peptide, insulin and glucagon concentration
were analyzed using an analysis of covariance (ANCOVA) model
with treatment as ﬁxed effect and the corresponding baseline value
(Day−1) as covariate. Least squares (LS) means and standard errors
for the change from baseline and the difference between lixisenatide
and placebo are provided.
Graphical presentations of the LS means with the corresponding
standard error (SE) are provided together with p-values for the treat-
ment comparisons (lixisenatide versus placebo), as well as the mean
blood glucose concentration–time proﬁles.
On the ranked gastric emptying parameter t½, an ANCOVA model
was applied with treatment as ﬁxed effect and the corresponding
ranked baseline value for t½, (Day−1) as a covariate. Descriptive sta-
tistics for t½ were provided for 20 μg lixisenatide QD and placebo
using the unranked values for t½. Statistical analyses were performed
using SAS® (SAS Institute, NC, USA).
The relationship between i) PPG–AUCbreakfast and the x-fold change at
Day 28 versusDay−1 (baseline) in gastric emptying (t½), ii) AUC–C-pep-
tide and PPG–AUCbreakfast, iii) AUC–C-peptide versus the x-fold change at
Day 28 versus Day−1 in gastric emptying (t½), iv) the x-fold change at
Day 28 versus Day−1 in gastric emptying (t½), and v) PPG–AUCbreakfastand gastric emptying at baseline (t½) were all evaluated using linear re-
gression analysis with GraphPad Prism (version 5.00 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.com). A
p-value of less than 0.05 was considered signiﬁcant in all analyses.
3. Results
3.1. Patient demographics and baseline characteristics
In total, 21 and 22 patients were randomized to lixisenatide and
placebo, respectively. In the lixisenatide group, 19 patients achieved
the maximum dose of 20 μg/day and were treated up to Day 28.
Apart from a slightly higher proportion of obese patients (i.e. BMI
≥30 kg/m2) in the lixisenatide group, demographic and baseline
characteristics were generally comparable between the two treat-
ment groups (Table 1). Clinical characteristics, including HbA1c and
FBG at screening, were also comparable.
3.2. Safety and tolerability
There were no serious treatment-emergent adverse events and no
signals identiﬁed from clinical laboratory tests, vital signs or ECG. The
overall incidence of treatment-emergent symptomatic hypoglycemia
was low (lixisenatide: two patients; placebo: one patient). One sub-
ject in the lixisenatide group had a hypoglycemic event considered
by the investigator as severe, although the event did not fulﬁll the
criteria for severe hypoglycemia and the subject recovered without
the need for assistance. None of the hypoglycemic events led to dis-
continuation of study medication. Of note, there was a low incidence
of nausea (two patients in each group) and no cases of vomiting in
the lixisenatide group (two cases in the placebo group); diarrhea
was reported by 4/21 patients with lixisenatide and no patients
with placebo.
3.3. Blood glucose, serum insulin, C-peptide and glucagon
Lixisenatide 20 μg QDwas associated with reductions versus pla-
cebo in PPG–AUC as well as maximum PPG (peak levels) from base-
line (Day−1) to Day 28 following all three meals (breakfast,
p b 0.0001; lunch, p b 0.001; and dinner, p b 0.05) (Fig. 1 and
Table 2). Hence, following administration of lixisenatide 20 μg QD in
the morning, there was a signiﬁcant pharmacodynamic effect on blood
glucose levels throughout the day. With placebo, PPG-AUC from base-
line to Day 28was not affected after breakfast, and therewas an increase
in glucose levels following lunch and dinner at Day 28 compared with
Fig. 1. Blood glucose concentrations and postprandial glucose in response to standardized meals at breakfast, lunch and dinner at baseline and Day 28 in patients with type 2 di-
abetes after administration of lixisenatide or placebo (mean ± standard error). SE = standard error; QD = once daily; LS = least squares; AUC = area under the curve.
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lixisenatide at Day 28 versus placebo was observed. Mean change in
HbA1c from baseline to Day 29 was −1.2% for lixisenatide 20 μg QD
and −0.6% for placebo, (p b 0.05). Serum insulin (p b 0.01) and
C-peptide (p b 0.05) were lower after breakfast for lixisenatide com-
pared with placebo (Table 2). Following breakfast, glucagon levels
were reduced with lixisenatide compared with placebo (p b 0.01,
Table 2).
3.4. Gastric emptying
Baseline gastric emptying (t½) values were comparable for
lixisenatide 20 μg QD and placebo. In the lixisenatide group, there
was a marked increase in the gastric emptying t½ versus baseline,
while there was no difference in t½ versus baseline in the placebo
group (p b 0.01) (Table 2).
3.5. Relationship of glycemia with gastric emptying
PPG–AUCbreakfast levels were inversely related to the magnitude of
slowing in gastric emptying (as measured by t½) for lixisenatide 20 μg
QD (r2 = 0.51, p b 0.05) but not for placebo (r2 = 0.06, ns) (Fig. 2A).
With lixisenatide 20 μg, there was an inverse correlation between the
extent of the reduction in PPG–AUC and C-peptide (r2 = 0.35,
p b 0.05) and for PPG–AUC and insulin (r2 = 0.38, p b 0.05, data not
shown), but not with placebo (r2 = 0.10, ns) (Fig. 2B). Finally, there
was a trend for an inverse correlationbetween C-peptide levels and gas-
tric emptying (lixisenatide: r2 = 0.16, ns; placebo: r2 = 0.12, ns)
(Fig. 2C).The changes in t½ with lixisenatide 20 μg were inversely related to
baseline t½, i.e. the magnitude of the slowing was greater when base-
line gastric emptying was more rapid (r2 = 0.39, p b 0.05) (Fig. 3A).
An inverse correlation was also evident between PPG–AUC levels and
baseline t½ (r2 = 0.37, p b 0.05) (Fig. 3B).
4. Discussion
GLP-1 receptor agonists modulate gastrointestinal motility and slow
gastric emptying in addition to their capacity to stimulate insulin and
suppress glucagon secretion in a glucose-dependent manner [3,4,16].
Therefore, as postprandial glycemic excursions are determined by the
rate of gastric emptying and insulin release is impaired in patients
with T2DM, slowing gastric emptying is a valid approach to attenuate
postprandial glycemic excursions and, thereby, to improve blood
glucose control. Targeting both FBG and PPG levels is recognized to be
pivotal for successful treatment of hyperglycemia [1]. However, as
HbA1c levels decrease as a result of diabetes therapy, consistent with
the Monnier model, postprandial glycemia is considered to contribute
to an increasingly greater extent to overall HbA1c compared with
pre-prandial/fasting glycemia [29]. Accordingly, control of postprandial
glycemia is essential to achieve HbA1c goals of b7% or 6.5% [30], which is
reﬂected by the guidelines from the International Diabetes Federation
for the management of postmeal glucose in diabetes [31]. Postprandial
hyperglycemiamay also be a direct, and independent, risk factor for car-
diovascular diseases [32]. The current study evaluated the effects of
lixisenatide, a new once-daily prandial GLP-1 receptor agonist for the
treatment of T2DM, on PPG (AUC and peak levels) after standardized
meals at breakfast, lunch and dinner, and on gastric emptying at
Table 2
Effects of lixisenatide and placebo on blood glucose, serum insulin, serum C-peptide, HbA1c, and gastric emptying.
LS means ± SE
Lixisenatide 20 μg QD Placebo Difference lixisenatide–
placebo
P-value
N Baseline
Day−1
Change from baseline to
Day 28
N Baseline
Day−1
Change from baseline to
Day 28
Postprandial blood glucose (h·mmol/L)
PPG–AUCbreakfast 19 52.7 ± 2.2 −21.5 ± 2.7 22 56.0 ± 2.1 −0.02 ± 2.5 −21.5 ± 3.6 b0.0001
PPG–AUClunch 19 49.4 ± 2.3 −10.3 ± 3.1 22 50.2 ± 2.2 5.7 ± 2.9 −16.0 ± 4.3 0.0004
PPG–AUCdinner 19 48.6 ± 2.7 −7.4 ± 3.0 22 49.4 ± 2.7 3.7 ± 2.8 −11.1 ± 4.1 0.0082
Maximum postprandial blood glucose (mmol/L)
After breakfast 19 13.0 ± 0.4 −3.9 ± 0.6 22 13.6 ± 0.3 0.9 ± 0.6 −4.8 ± 0.8 b0.0001
After lunch 19 11.6 ± 0.5 −1.2 ± 0.7 22 11.8 ± 0.5 2.4 ± 0.7 −3.6 ± 1.0 0.0006
After dinner 19 11.3 ± 0.6 −0.6 ± 0.7 22 11.3 ± 0.6 1.7 ± 0.7 −2.3 ± 1.0 0.0228
Insulin–AUCbreakfast(h·μIU/mL) 18 98.8 ± 13.7 −7.4 ± 13.7 21 105.5 ± 12.7 49.4 ± 12.8 –56.8 ± 18.6 0.0037
C-peptide–AUCbreakfast (h·ngl/mL) 18 9.1 ± 1.1 0.8 ± 1.3 21 10.5 ± 1.0 4.6 ± 1.2 –3.8 ± 1.7 0.0345
Fasting blood glucose (mmol/L) 19 8.7 ± 0.4 −1.9 ± 0.5 22 8.8 ± 0.4 −0.7 ± 0.5 −1.3 ± 0.7 0.0752
HbA1c (%) 19 8.5 ± 0.3 −1.2 ± 0.2 20 8.9 ± 0.2 −0.6 ± 0.2 −0.6 ± 0.2 0.0184
Glucagon–AUCbreakfast relative to
pre-breakfast (h·pmol/L)
18 21.2 ± 2.7 −19.6 ± 3.9 21 14.1 ± 3.5 −4.4 ± 3.6 −15.2 ± 5.4 0.0066
Gastric emptying time t1/2 (min)a 17 245.3 ± 25.0 211.5 ± 67.6 17 237.9 ± 23.1 –24.1 ± 32.3 235.6 ± 74.9 0.0031
LS = least square; SE = standard error; AUC = area under the curve; PPG = postprandial glucose; QD = once daily.
a Mean ± SE.
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emptying. The results indicate that in patients with T2DM on oral
antidiabetic therapy, lixisenatide 20 μg administered once daily in the
morning reduces PPG levels throughout the day, and that the reduction
in PPG at least after breakfast is attributable to retardation of gastric
emptying.
The effect of GLP-1 receptor agonists on gastric emptying has often
been assessed using imprecise techniques such as the acetaminophen
test [16,33–35]. In this study, gastric emptying of breakfast was mea-
sured using the more accurate radiolabeled breath test technique and
was shown to bemarkedly slowed by lixisenatide 20 μg QDwhen com-
pared with placebo. Importantly, the magnitude of the reduction in
PPG–AUC after breakfast was shown to be related closely to the degree
of slowed gastric emptying (Fig. 2A) and was not associated with a rise
in insulin, supporting the concept that blunting PPG–AUC through
GLP-1 receptor agonism can be achieved predominantly by slowing of
gastric emptying [5]. The assumption that the reduced insulin response
is related to the reduction in PPG–AUC is supported by the observed
correlation between PPG and C-peptide (Fig. 2B) and insulin levels
(data not shown) for lixisenatide. There was also a trend for an inverse
relationship between C-peptide (Fig. 2C) and insulin (data not shown)
and retardation of gastric emptying. Hence, as is the case for native
GLP-1when administered exogenously, the slowing of gastric emptying
induced by lixisenatide appears to outweigh its insulinotropic proper-
ties, at least after the ﬁrst meal. Reduced glucagon levels following the
breakfast meal (Table 2) were observed with lixisenatide compared
with placebo. A reduction of postprandial glucagon secretion is a
known effect of GLP-1 and GLP­1 receptor agonists, whichmay contrib-
ute to the lowering of blood glucose concentrations [1–3]. Whether the
reduction in PPG–AUC at subsequent meals also reﬂects inhibition of
gastric emptying, and/or is a result of enhanced insulin release, gluca-
gon suppression, or both, warrants evaluation.
Indirect comparison of the effects of lixisenatide with marketed
GLP-1 receptor agonists, exenatide BID and LAR, and liraglutide QD, in-
dicates that the impact on gastric emptying and resulting reduction in
PPG–AUC are important differentiating characteristics within this class
that are dependent on the pharmacokinetics of the individual agent.
For the longer-acting GLP-1 receptor agonist liraglutide, there is evi-
dence that the sustained 24-hour exposure results in receptor desensi-
tization and tachyphylaxis to the slowing of gastric emptying which is
within 2 weeks of treatment in rats [33]. These data are consistentwith an apparently modest delay in gastric emptying, limited to 1 h
post-meal, reported in patients with T2DM after 3 weeks of treatment
with liraglutide [15]. A minor effect on gastric emptying has also been
reported for exenatide LAR,which has been considered not to be of clin-
ical relevance [36]. In contrast to longer-acting agents, and similar to the
ﬁndings with lixisenatide, PPG levels and the slowing of gastric empty-
ing are inversely correlated in patients with T2DM treated with the
shorter-acting exenatide BID [5]. Although not reported in this paper,
the changes from baseline for the gastric emptying half-time at break-
fast were comparable after once- versus twice-daily dosing of
lixisenatide i.e. 20 μg QD or BID (t1/2 QD = 211.5 ± 278.50 min; t1/2
BID = 202.3 ± 229.98 min). These data are consistent with the effect
of BID administered exenatide and do not suggest desensitization/
tachyphylaxis to the slowing of gastric emptying with BID-dosing of
lixisenatide. A sustained slowing of gastric emptying is, accordingly,
likely to account for the observed greater reduction in PPG for the
shorter-acting agents, for example in clinical head-to-head compari-
sons of exenatide BID versus liraglutide [37] and lixisenatide versus
liraglutide [18]. The mean terminal half-life of approximately 3 h in
humans characterizes lixisenatide as a shorter-acting GLP-1 receptor
agonist, like exenatide BID. Lixisenatide is also characterized by a strong
binding afﬁnity to the GLP-1 receptor, which is approximately four-fold
greater than the afﬁnity of native GLP-1 [38]. The shorter half-life of
lixisenatide combined with a strong afﬁnity for the GLP-1 receptor
may allow a distinct period of time between injectionswithout receptor
activation to circumvent the mechanism of tachyphylaxis and ensure a
sustained effect to slow gastric emptying, resulting in amajor reduction
in PPG. These considerations are of relevance for the combination of a
GLP-1 receptor agonist and basal insulin in T2DM patients. Comple-
menting the FBG beneﬁts of basal insulin with the greater PPG-
lowering effects of a shorter-acting GLP-1 receptor agonist may be
more effective than combining with longer-acting agents that rely on
a sustained insulinotropic effect and, like basal insulin products,
predominantly reduce FBG. For patients with improved HbA1c under
therapy (including those on insulin treatment), who have a greater de-
pendency on postprandial glucose, lixisenatide or exenatide BID are
likely to be sound choices.
In summary, this study shows that in patients with T2DM,
lixisenatide injection (20 μg) in the morning reduces postprandial gly-
cemic excursions throughout the day, which (at least after breakfast)
is accounted for by a sustained slowing of gastric emptying.
Fig. 2. Regression analysis for (A) AUC–PPGbreakfast with gastric emptying (t1/2); (B) C-peptide AUCbreakfast and AUC–PPG; (C) C-peptide AUCbreakfast and gastric emptying (t1/2) for
lixisenatide 20 μg once daily and placebo. N = 17 for all. t½ = gastric 50% emptying time; AUC = area under the curve; PPG = postprandial glucose.
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Results from this randomized, double-blind, placebo-controlled,
parallel-group study using an ascending dose range of (5–20 μg)Fig. 3. Regression analysis for (A) Change of t1/2 from baseline to Day 28 and gastric empty
Day 28 and gastric emptying (t1/2); at baseline (Day−1) for lixisenatide 20 μg once daily.increased every ﬁfth day in increments of 2.5 μg demonstrated that
lixisenatide 20 μg QD reduced PPG from baseline to Day 28 at all
meals (breakfast, lunch and dinner). Gastric emptying (50% emptying
time) increased substantially from baseline with lixisenatide 20 μging (t1/2) at baseline (Day−1), and (B) AUC–PPGbreakfast with gastric emptying (t1/2) at
7M. Lorenz et al. / Regulatory Peptides 185 (2013) 1–8QD, but not with placebo. There was an inverse relationship between
PPG–AUC following a standardized breakfast and gastric emptying
with lixisenatide 20 μg QD. In conclusion, lixisenatide 20 μg QD re-
duced postprandial glycemic excursions in patients with T2DM, likely
as a result of sustained slowing of gastric emptying.
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